Journal article
FoxO1-zDHHC4-CD36 S-acylation axis drives metabolic dysfunction in diabetes
- Abstract:
-
BACKGROUND:
The fatty acid (FA) transporter CD36 (FA translocase/cluster of differentiation 36) is the gatekeeper of cardiac FA metabolism. Preferential localization of CD36 to the sarcolemma is one of the initiating cellular responses in the development of muscle insulin resistance and the type 2 diabetic heart. Posttranslational S-acylation controls protein trafficking, and in this study, we hypothesized that increased CD36 S-acylation may underpin the preferential sarcolemmal localization of CD36, driving metabolic and contractile dysfunction in diabetes.
METHODS:
Type 2 diabetes was induced in the rat using high fat diet and a low dose of streptozotocin. Forkhead box O1 (FoxO1) transcriptional regulation of zDHHC4 (zinc finger DHHC-type palmitoyltransferase 4) and subsequent S-acylation of CD36 was assessed using chromatin immunoprecipitation (ChIP) sequencing, ChIP-quantitative polymerase chain reaction, luciferase assays, siRNA (small interfering RNA) and shRNA silencing.
RESULTS:
Type 2 diabetes increased cardiac CD36 S-acylation, CD36 sarcolemmal localisation, FA oxidation rates and triglyceride storage in the diabetic heart. CD36 S-acylation was increased in diabetic rats, db/db mice, diabetic pigs and insulin-resistant human iPSC-derived cardiomyocytes, demonstrating conservation between species. The enzyme responsible for S-acylating CD36, zDHHC4, was transcriptionally upregulated in the diabetic heart, and genetic silencing of zDHHC4 decreased CD36 S-acylation. We identified that zDHHC4 expression is under the regulation of the transcription factor FoxO1. Diabetic mice with cardiomyocyte-specific FoxO1 deletion had decreased cardiac zDHHC4 expression and decreased CD36 S-acylation, which was further confirmed using diabetic mice treated with the FoxO1 inhibitor AS1842856. Pharmacological inhibition of zDHHC enzymes in diabetic hearts decreased CD36 S-acylation, sarcolemmal CD36 content, FA oxidation rates and triglyceride storage, culminating in improved cardiac function in diabetes. Conversely, inhibiting the de-acylating enzymes in control hearts increased CD36 S-acylation, sarcolemmal CD36 content and FA metabolic rates in control hearts, recapitulating the metabolic phenotype seen in diabetic hearts.
CONCLUSIONS:
Activation of the FoxO1-zDHHC4-CD36 S-acylation axis in diabetes drives metabolic and contractile dysfunction in type 2 diabetic heart.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Supplementary materials, zip, 3.9MB, Terms of use)
-
(Preview, Version of record, pdf, 4.9MB, Terms of use)
-
- Publisher copy:
- 10.1161/CIRCRESAHA.124.325918
Authors
+ Hartstichting
More from this funder
- Funder identifier:
- https://ror.org/05nxhgm70
- Grant:
- 2020B008 RECONNEXT
+ Wellcome Trust
More from this funder
- Funder identifier:
- https://ror.org/029chgv08
- Grant:
- 218514/Z/19/Z
- 221604/Z/20/Z
+ British Heart Foundation
More from this funder
- Funder identifier:
- https://ror.org/02wdwnk04
- Grant:
- FS/19/61/34900
- FS/17/58/33072
+ National Institutes of Health
More from this funder
- Funder identifier:
- https://ror.org/01cwqze88
- Grant:
- R35 GM119840
+ European Cooperation in Science and Technology
More from this funder
- Funder identifier:
- https://ror.org/01bstzn19
- Grant:
- CA22169
- Publisher:
- American Heart Association
- Journal:
- Circulation Research More from this journal
- Volume:
- 136
- Issue:
- 12
- Pages:
- 1545-1560
- Place of publication:
- United States
- Publication date:
- 2025-05-13
- Acceptance date:
- 2025-04-23
- DOI:
- EISSN:
-
1524-4571
- ISSN:
-
0009-7330
- Pmid:
-
40357580
- Language:
-
English
- Keywords:
- Pubs id:
-
2123596
- Local pid:
-
pubs:2123596
- Deposit date:
-
2025-06-11
- ARK identifier:
Terms of use
- Copyright holder:
- Dennis et al.
- Copyright date:
- 2025
- Rights statement:
- © 2025 The Authors.Circulation Research is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record